131 related articles for article (PubMed ID: 31566983)
1. Diagnostic and Prognostic Performance of Blood Plasma Glycan Features in the Women Epidemiology Lung Cancer (WELCA) Study.
Hu Y; Ferdosi S; Kapuruge EP; Diaz de Leon JA; Stücker I; Radoï L; Guénel P; Borges CR
J Proteome Res; 2019 Nov; 18(11):3985-3998. PubMed ID: 31566983
[TBL] [Abstract][Full Text] [Related]
2. Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer.
Ferdosi S; Rehder DS; Maranian P; Castle EP; Ho TH; Pass HI; Cramer DW; Anderson KS; Fu L; Cole DEC; Le T; Wu X; Borges CR
J Proteome Res; 2018 Jan; 17(1):543-558. PubMed ID: 29129073
[TBL] [Abstract][Full Text] [Related]
3. Behavior of blood plasma glycan features in bladder cancer.
Ferdosi S; Ho TH; Castle EP; Stanton ML; Borges CR
PLoS One; 2018; 13(7):e0201208. PubMed ID: 30040854
[TBL] [Abstract][Full Text] [Related]
4. Exploring serum and immunoglobulin G N-glycome as diagnostic biomarkers for early detection of breast cancer in Ethiopian women.
Gebrehiwot AG; Melka DS; Kassaye YM; Gemechu T; Lako W; Hinou H; Nishimura SI
BMC Cancer; 2019 Jun; 19(1):588. PubMed ID: 31208374
[TBL] [Abstract][Full Text] [Related]
5. Enrichment strategies in glycomics-based lung cancer biomarker development.
Ruhaak LR; Nguyen UT; Stroble C; Taylor SL; Taguchi A; Hanash SM; Lebrilla CB; Kim K; Miyamoto S
Proteomics Clin Appl; 2013 Oct; 7(9-10):664-76. PubMed ID: 23640812
[TBL] [Abstract][Full Text] [Related]
6. Altered desialylated plasma N-glycan profile in patients with non-small cell lung carcinoma.
Bartling B; Vanhooren V; Dewaele S; Libert C; Hofmann HS; Haerting J; Nuding S; Silber RE; Simm A; Chen CC
Cancer Biomark; 2011-2012; 10(3-4):145-54. PubMed ID: 22674300
[TBL] [Abstract][Full Text] [Related]
7. The Repertoire of Glycan Alterations and Glycoproteins in Human Cancers.
Kori M; Aydin B; Gulfidan G; Beklen H; Kelesoglu N; Caliskan Iscan A; Turanli B; Erzik C; Karademir B; Arga KY
OMICS; 2021 Mar; 25(3):139-168. PubMed ID: 33404348
[TBL] [Abstract][Full Text] [Related]
8. Glycans as cancer biomarkers.
Adamczyk B; Tharmalingam T; Rudd PM
Biochim Biophys Acta; 2012 Sep; 1820(9):1347-53. PubMed ID: 22178561
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles.
Kyselova Z; Mechref Y; Kang P; Goetz JA; Dobrolecki LE; Sledge GW; Schnaper L; Hickey RJ; Malkas LH; Novotny MV
Clin Chem; 2008 Jul; 54(7):1166-75. PubMed ID: 18487288
[TBL] [Abstract][Full Text] [Related]
10. Association of N-glycosylation with breast carcinoma and systemic features using high-resolution quantitative UPLC.
Saldova R; Asadi Shehni A; Haakensen VD; Steinfeld I; Hilliard M; Kifer I; Helland A; Yakhini Z; Børresen-Dale AL; Rudd PM
J Proteome Res; 2014 May; 13(5):2314-27. PubMed ID: 24669823
[TBL] [Abstract][Full Text] [Related]
11. Smoking and lung cancer-induced changes in N-glycosylation of blood serum proteins.
Vasseur JA; Goetz JA; Alley WR; Novotny MV
Glycobiology; 2012 Dec; 22(12):1684-708. PubMed ID: 22781126
[TBL] [Abstract][Full Text] [Related]
12. Differential N-Glycosylation Patterns in Lung Adenocarcinoma Tissue.
Ruhaak LR; Taylor SL; Stroble C; Nguyen UT; Parker EA; Song T; Lebrilla CB; Rom WN; Pass H; Kim K; Kelly K; Miyamoto S
J Proteome Res; 2015 Nov; 14(11):4538-49. PubMed ID: 26322380
[TBL] [Abstract][Full Text] [Related]
13. Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer.
Zhao YP; Zhou PT; Ji WP; Wang H; Fang M; Wang MM; Yin YP; Jin G; Gao CF
Clin Exp Med; 2017 Feb; 17(1):9-18. PubMed ID: 26714469
[TBL] [Abstract][Full Text] [Related]
14. Glycosylation Profiling of Glycoproteins Secreted from Cultured Cells Using Glycan Node Analysis and GC-MS.
Aguilar Díaz de León JS; Borges CR
Methods Mol Biol; 2021; 2271():317-330. PubMed ID: 33908017
[TBL] [Abstract][Full Text] [Related]
15. N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients.
Alley WR; Vasseur JA; Goetz JA; Svoboda M; Mann BF; Matei DE; Menning N; Hussein A; Mechref Y; Novotny MV
J Proteome Res; 2012 Apr; 11(4):2282-300. PubMed ID: 22304416
[TBL] [Abstract][Full Text] [Related]
16. Novel glycan biomarkers for the detection of lung cancer.
Arnold JN; Saldova R; Galligan MC; Murphy TB; Mimura-Kimura Y; Telford JE; Godwin AK; Rudd PM
J Proteome Res; 2011 Apr; 10(4):1755-64. PubMed ID: 21214223
[TBL] [Abstract][Full Text] [Related]
17. Distinguishing Benign and Malignant Thyroid Nodules and Identifying Lymph Node Metastasis in Papillary Thyroid Cancer by Plasma
Zhang Z; Reiding KR; Wu J; Li Z; Xu X
Front Endocrinol (Lausanne); 2021; 12():692910. PubMed ID: 34248851
[TBL] [Abstract][Full Text] [Related]
18. Characterization of IgG N-glycome profile in colorectal cancer progression by MALDI-TOF-MS.
Liu S; Cheng L; Fu Y; Liu BF; Liu X
J Proteomics; 2018 Jun; 181():225-237. PubMed ID: 29698801
[TBL] [Abstract][Full Text] [Related]
19. Relative Quantification and Higher-Order Modeling of the Plasma Glycan Cancer Burden Ratio in Ovarian Cancer Case-Control Samples.
Hecht ES; Scholl EH; Walker SH; Taylor AD; Cliby WA; Motsinger-Reif AA; Muddiman DC
J Proteome Res; 2015 Oct; 14(10):4394-401. PubMed ID: 26347193
[TBL] [Abstract][Full Text] [Related]
20. Human disease glycomics: technology advances enabling protein glycosylation analysis - part 1.
Everest-Dass AV; Moh ESX; Ashwood C; Shathili AMM; Packer NH
Expert Rev Proteomics; 2018 Feb; 15(2):165-182. PubMed ID: 29285957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
